3 Jul

JNJ’s Infectious Diseases Segment Witnessed ~11% YoY Growth

WRITTEN BY Daniel Collins FEATURED IN Company News, Insights, & Analysis

Infectious diseases: Revenue trends

In the first quarter, Johnson & Johnson’s (JNJ) Infectious Diseases segment generated revenues of $830.0 million compared to $749.0 million in the first quarter of 2017, which reflected ~10.8% YoY (year-over-year) growth.

Johnson & Johnson’s Infectious Diseases segment reported revenues of $333.0 million and $497.0 million in the first quarter from its sales in the US and international markets, respectively, which reflected ~2.1% and ~17.5% YoY growth.

JNJ’s Infectious Diseases Segment Witnessed ~11% YoY Growth

Edurant’s revenue trends

In the first quarter, Edurant’s revenues grew 40.9% to reach $210.0 million, including revenues of $14.0 million and $196.0 million, respectively, from the sales in the US and international markets.

In the US and international markets, Edurant witnessed first-quarter growth of ~16.7% and ~43.1%, respectively, on a YoY basis. Edurant is used for the treatment of individuals with HIV-1 infection.

Prezista/Prezcobix/Rezolsta/Symtuza: Revenue trends

In the first quarter, Prezista/Prezcobix/Rezolsta/Symtuza reported net revenues of $478.0 million compared to $430.0 million in the first quarter of 2017, reflecting ~11.0% YoY growth.

In the US, Prezista/Prezcobix/Rezolsta/Symtuza generated first-quarter net revenues of $273.0 million for ~5.4% YoY growth. In the international market, it generated revenues of $205.0 million for ~19.9% YoY growth.

Other infectious disease product revenues

Johnson & Johnson’s other infectious disease products reported revenues of $142.0 million, including revenues of $46.0 million and $96.0 million from the US and international markets.

The solid sales growth of Edurant and Prezcobix/Rezolsta drove the revenue growth of JNJ’s Infectious Diseases segment. The sales growth of Odefsey also pushed the revenue growth of the segment.

The launch of Symtuza positively impacted Johnson & Johnson’s Infectious Diseases segment, which was partially offset by the decline in sales of Olysio and Prezista.

In the anti-hepatitis C virus infection drugs market, Johnson & Johnson’s Olysio faces competition from Gilead Sciences’ (GILD) Harvoni and Merck’s (MRK) Zepatier. Harvoni and Zepatier reported first-quarter revenues of $348.0 million and $131.0 million, respectively.

Latest articles

Monster Beverage (MNST) stock was down 1.6% as of 2:47 PM EDT on March 20.

Earlier today, the second-largest US automaker by 2018 sales volume, Ford Motor Company (F), revealed its plan to invest $850 million in its Flat Rock assembly plant through 2023.

Mizuho downgraded Yum! Brands (YUM) from “neutral” to “underperform” while keeping its 12-month price unchanged at $84, which represents a fall of 15.4% from its March 19 closing price of $99.20.

20 Mar

Why Verizon Sought to Lead 5G Rollout

WRITTEN BY Rachel Gunter

According to Verizon, its mobile 5G plans will cost $10 more than its current 4G plans.

As of March 19, Dunkin’ Brands (DNKN) was trading at $71.55, which represents a rise of 3.9% since the announcement of its fourth-quarter earnings on February 7.

Suncor Energy's shareholder returns have grown consistently over the past few years. The company hasn't forgotten its commitment to growth.